Yahoo Suche Web Suche

Suchergebnisse

  1. Suchergebnisse:
  1. Vor 2 Tagen · Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business. The company developed a broad biologics pipeline including a wholly-owned product for a rare hematologic indication, which was approved for ...

  2. Vor 4 Tagen · Tokyo silver medalist Rai Benjamin delivers a strong performance by winning the men's 400m hurdles at the USATF LA Grand Prix, crossing the line in 46.64 sec...

    • 4 Min.
    • 42,4K
    • NBC Sports
  3. Vor einem Tag · Dr. Edwin Moses, Chairman of LabGenius’ Board and former CEO of Ablynx, added: “Closing a round of this size and with such high-quality investors is a testament both to the power and potential of the LabGenius platform and also the quality and dedication of the LabGenius team. We look forward to using our unique and powerful platform to develop new medicines to meet high unmet medical ...

  4. Vor einem Tag · Dr. Edwin Moses, chairman of Labgenius’ board, said: “Closing a round of this size and with such high-quality investors is a testament both to the power and potential of the Labgenius platform ...

  5. Vor einem Tag · Olympiasieger Edwin Moses (hier im Jahr 1987) mit seinem ersten großen internationalen Erfolg → Hauptartikel : Olympische Sommerspiele 1976/Leichtathletik – 400 m Hürden (Männer) Platz

    • Männer: 23/Frauen: 14
    • Montreal
  6. Vor 4 Tagen · Benjamin dominates 400m hurdles at LA Grand Prix. May 18, 2024 03:48 PM. Tokyo silver medalist Rai Benjamin delivers a strong performance by winning the men's 400m hurdles at the USATF LA Grand Prix, crossing the line in 46.64 seconds to break Edwin Moses' track record at Drake Stadium. Stay in the Know. Subscribe to our Newsletter and Alerts.

  7. Vor einem Tag · Abliva AB (Publ) gibt den Rücktritt von Edwin Moses als Direktor bekannt. 04.05.23. CI. Abliva legt um 15% zu, nachdem die US Food and Drug Administration (FDA) den Medikamentenkandidaten für mitochondriale Erkrankungen als Arzneimittel für seltene Leiden eingestuft hat. 17.04.23.